Black Diamond Therapeutics, Inc. (BDTX) Stock Score, Valuation & Financial Research
Black Diamond Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for BDTX
Black Diamond Therapeutics, Inc. currently has a Wall Street Score of 35/100. The stored market price is $1.98. Its financial score is 35/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Black Diamond Therapeutics, Inc. does
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Sof
BDTX financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $1.98
- Market capitalization:
- $113.5M
- Revenue:
- $0
- Net income:
- $-42.6M
- Free cash flow:
- $29.6M
- Cash:
- $19.2M
- Total debt:
- $17.0M
- EPS:
- -0.74
- Financial score:
- 35/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -1.0%.
- Free cash flow is $29.6M, showing positive cash generation.
- The balance sheet shows $19.2M of cash versus $17.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: BDTX decreased 0.1 points because some fundamentals weakened.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 35/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BDTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.